Cargando…

Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma

PURPOSE: Oropharyngeal squamous cell carcinoma (OSCC) has been recognized as an immunosuppressive disease. Various mechanisms have been proposed for immune escape, including dysregulation of immune checkpoints such as the PD-1:PD-L1 pathway. We investigated the expression of programmed cell death-li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hae Su, Lee, Ji Yun, Lim, Sung Hee, Park, Keunchil, Sun, Jong-Mu, Ko, Young Hyeh, Baek, Chung-Hwan, Son, Young-ik, Jeong, Han Sin, Ahn, Yong Chan, Lee, Min-Young, Hong, Mineui, Ahn, Myung-Ju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843713/ https://www.ncbi.nlm.nih.gov/pubmed/26511814 http://dx.doi.org/10.4143/crt.2015.249

Ejemplares similares

Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs
por: Kim, Kyung Hwan, et al.
Publicado: (2020)

High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma
por: Ku, Bo Mi, et al.
Publicado: (2014)

Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
por: Jung, Hae Il, et al.
Publicado: (2017)

Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer
por: Lee, Min-Young, et al.
Publicado: (2017)

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy
por: Shin, Kabsoo, et al.
Publicado: (2023)

Prognostic implications of PD-L1 expression in patients with angiosarcoma
por: Lee, Jii Bum, et al.
Publicado: (2021)

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment
por: Kim, Kyung Hwan, et al.
Publicado: (2020)

Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
por: Jung, Hyun Ae, et al.
Publicado: (2022)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Ocular adverse events in PD-1 and PD-L1 inhibitors
por: Young, LeAnne, et al.
Publicado: (2021)

Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression
por: Xu, Sheng-ming, et al.
Publicado: (2022)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
por: Jeong, Seri, et al.
Publicado: (2021)

Regulatory (FoxP3(+)) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer
por: Koh, Jiae, et al.
Publicado: (2020)

The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs
por: Kim, Seung Tae, et al.
Publicado: (2016)

PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence
por: Byeon, Seonggyu, et al.
Publicado: (2020)

Kaempferol and Its Glycoside, Kaempferol 7-O-rhamnoside, Inhibit PD-1/PD-L1 Interaction In Vitro
por: Kim, Ji Hye, et al.
Publicado: (2020)

Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma
por: Blatt, Sebastian, et al.
Publicado: (2022)

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma
por: Cho, Inju, et al.
Publicado: (2020)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

CD30-Positive T-Cell Lymphoproliferative Disease of the Oral Mucosa in Children: A Manifestation of Epstein-Barr Virus-Associated T-Lymphoproliferative Disorder
por: Hong, Mineui, et al.
Publicado: (2015)

Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors
por: Song, Doo-Won, et al.
Publicado: (2021)

CD8+ T Cells and PD-L1 Expression as Prognostic Indicators in a Low Prevalence of HPV-Associated Oropharyngeal Squamous Cell Carcinoma
por: Atipas, Kawita, et al.
Publicado: (2023)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model
por: Lee, Eun-Ji, et al.
Publicado: (2021)

MDSC subtypes and CD39 expression on CD8(+) T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC
por: Koh, Jiae, et al.
Publicado: (2020)

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression
por: Koh, Young Wha, et al.
Publicado: (2017)

siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model
por: Jung, Jae Yun, et al.
Publicado: (2021)

Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma
por: Kim, Chan, et al.
Publicado: (2016)

Increased PD-L1 and p16 expression are common in oropharyngeal squamous cell carcinoma
por: Shestakova, Anna, et al.
Publicado: (2021)

Correlation of PD-L1 expression with toxicities and response in oropharyngeal cancers treated with definitive chemoradiotherapy
por: Srivastava, Smriti, et al.
Publicado: (2022)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

High‐affinity PD‐1 molecules deliver improved interaction with PD‐L1 and PD‐L2
por: Li, Yanyan, et al.
Publicado: (2018)

PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection
por: Lyu, Xintong, et al.
Publicado: (2019)

PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
por: Kim, Sang Kyum, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6ah6tb3fgdvudajogt3937m3b7